Characterization of retrovirus-based vectors used in gene and cell therapies

Retrovirus-based vectors used in gene and cell therapies may be characterized with light scattering instruments and separations systems from Wyatt Technology.

Image Credit: ShuterStock/Kateryna Kon

Lentivirus and gamma retrovirus are two extremely popular retrovirus-based vectors currently being developed for novel gene and cell therapies. As of 2021, there were over three hundred products in clinical trials.

Accurate quantitation with comprehensive and reliable characterization is essential for ensuring the quality and efficacy of retroviral gene vectors. However, the inherent complexity of these products leads to significant analytical challenges. This application note from Wyatt Technology describes two technologies for biophysical characterization of viral vectors based on light scattering: high-throughput dynamic light scattering (HT-DLS) for quantitation and screening, and field-flow fractionation coupled to multi-angle light scattering (FFF-MALS) for in-depth characterization.

Click here to read the full article

About Wyatt Technology

With a long history of excellence in scientific instrumentation, Wyatt Technology is the recognized leader in innovative light scattering instruments, accessories and software for determining the properties of macromolecules and nanoparticles in solution. Wyatt's  cutting-edge solutions determine the size, physical titer, payload and zeta potential of nanoparticles, as well as the molar mass, size, conformation, conjugation and interactions of macromolecules. With a staff composed of 25% Ph.D. scientists and many more dedicated and experienced support personnel, Wyatt's aim is to delight its customer with the best products, training, customer support and service available in the industry.


Sponsored Content Policy: News-Medical.net publishes articles and related content that may be derived from sources where we have existing commercial relationships, provided such content adds value to the core editorial ethos of News-Medical.Net which is to educate and inform site visitors interested in medical research, science, medical devices and treatments.

Last updated: Sep 19, 2023 at 4:45 AM

Citations

Please use one of the following formats to cite this article in your essay, paper or report:

  • APA

    Waters | Wyatt Technology. (2023, September 19). Characterization of retrovirus-based vectors used in gene and cell therapies. News-Medical. Retrieved on November 21, 2024 from https://www.news-medical.net/whitepaper/20230222/Retrovirus-based-vectors-used-in-novel-gene-and-cell-therapies.aspx.

  • MLA

    Waters | Wyatt Technology. "Characterization of retrovirus-based vectors used in gene and cell therapies". News-Medical. 21 November 2024. <https://www.news-medical.net/whitepaper/20230222/Retrovirus-based-vectors-used-in-novel-gene-and-cell-therapies.aspx>.

  • Chicago

    Waters | Wyatt Technology. "Characterization of retrovirus-based vectors used in gene and cell therapies". News-Medical. https://www.news-medical.net/whitepaper/20230222/Retrovirus-based-vectors-used-in-novel-gene-and-cell-therapies.aspx. (accessed November 21, 2024).

  • Harvard

    Waters | Wyatt Technology. 2023. Characterization of retrovirus-based vectors used in gene and cell therapies. News-Medical, viewed 21 November 2024, https://www.news-medical.net/whitepaper/20230222/Retrovirus-based-vectors-used-in-novel-gene-and-cell-therapies.aspx.

Other White Papers by this Supplier

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.